Thiamine Hydrochloride
FDA-approved product (injectable, injection), marketed as Betalin S, Thiamine Hydrochloride.
- Registered studies
- 50+
- Lab records
- 0
- Pathogens at ≥40%
- 2 of 4
Chemical structure
Existing / approved use
Documented · FDA, WHO, ChEMBLApproved for
- Anemia (phenotype)
- Chronic kidney disease
- Encephalopathy
- Iron deficiency anemia
- Thiamine deficiency
Indications ChEMBL records as approved, from FDA and DailyMed labels. Label ↗
- WHO therapeutic group
- Vitamin b1, plain
- Anti-infective classification
- Not classified as an anti-infective.
Repurposing investigation
This medicine is being investigated here for AI-predicted antimicrobial activity against MRSA and E. coli. It was surfaced computationally for further investigation; it is not an established treatment for these infections.
AI-predicted activity
AI prediction · nothing measured- MRSA41.0% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
- E. coli50.4% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
- K. pneumoniae20.7% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
- M. tuberculosis34.4% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
A model’s estimate of laboratory activity against each pathogen species. It is not clinical effectiveness.
Evidence
Clinical and experimental
Documented evidenceClinical
50+registered studies name this medicine, for any condition. The registry search keeps the first 50, so there may be more. See them below.
Experimental
No evidence found
No laboratory measurement against the four pathogens in the ChEMBL records loaded here.
Docking
Computational · nothing measuredAutoDock Vina, one experimentally solved protein per pathogen. This project’s screening target is -7.0 kcal/mol, its own mark rather than a universal cutoff. A docking score is a structural hypothesis, not proof of binding, and requires experimental validation.
Other medicines to investigate
AI prediction · nothing measuredOther repurposing candidates: approved medicines besides Thiamine Hydrochloride with AI-predicted activity ≥40% against the chosen pathogen, leaving out existing antimicrobials. They are computational candidates for further investigation, not alternatives and not recommendations.
Sorted by AI-predicted activity, high to low. The order is not a ranking of which medicine is better.
- Mefloquine HydrochlorideExisting use: Malaria, Plasmodium falciparum malaria, Plasmodium vivax malaria81.8% AI-predicted activityagainst M. tuberculosisLab records exist8 registered studies
- KetoconazoleExisting use: Adrenal gland disease, Blastomycosis, Cushing syndrome and 3 more81.2% AI-predicted activityagainst M. tuberculosisLab records exist50+ registered studies
- LevoketoconazoleExisting use: Adrenal gland disease, Adrenal gland hyperfunction, Cushing syndrome81.2% AI-predicted activityagainst M. tuberculosis6 registered studies
- Fluphenazine DecanoateExisting use: Mental or behavioural disorder, Psychosis80.7% AI-predicted activityagainst M. tuberculosis4 registered studies
- Fluphenazine EnanthateExisting use: Mental or behavioural disorder, Psychosis80.7% AI-predicted activityagainst M. tuberculosisNo documented evidence found
- NifurtimoxExisting use: American trypanosomiasis, Chagas disease, Leishmaniasis and 1 more78.4% AI-predicted activityagainst M. tuberculosis19 registered studies
- Fluphenazine HydrochlorideExisting use: Mental or behavioural disorder, Psychosis77.8% AI-predicted activityagainst M. tuberculosis5 registered studies
- NitazoxanideExisting use: Amebiasis, Diarrhea77.8% AI-predicted activityagainst M. tuberculosisLab records exist50+ registered studies
- TopiramateExisting use: Epilepsy, Lennox-Gastaut syndrome, Migraine disorder and 1 more77.4% AI-predicted activityagainst M. tuberculosisLab records exist50+ registered studies
- TrabectedinExisting use: Cancer, Dedifferentiated liposarcoma, Leiomyosarcoma and 7 more76.8% AI-predicted activityagainst M. tuberculosis50+ registered studies
- Chlorpromazine HydrochlorideExisting use: Conduct disorder, Mental or behavioural disorder, Nausea and vomiting and 3 more75.0% AI-predicted activityagainst M. tuberculosis33 registered studies
- ProchlorperazineExisting use: Anxiety disorder, Nausea and vomiting, Psychosis and 1 more74.1% AI-predicted activityagainst M. tuberculosis50+ registered studies
Registered studies
A registration describes a study; it does not establish a positive result.
Neuropathic Pain Management
NCT01263132 · start 2008-02
Registered record
- Registry ID
- NCT01263132
- Conditions
- Diabetic Neuropathies; Polyneuropathies
- Interventions
- F0434; Gabapentin
- Study type
- INTERVENTIONAL
- Phase
- Phase 3
- Registry status
- Completed
- Start
- 2008-02
- Completion
- 2010-02
- Enrolment
- 104
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionDiabetic Neuropathies; PolyneuropathiesInterventionF0434; GabapentinPhasePhase 3Registry statusCompletedEffectiveness of Dalteparin Therapy as Intervention in Recurrent Pregnancy Loss
NCT00400387 · start 2006-11
Registered record
- Registry ID
- NCT00400387
- Conditions
- Abortion, Habitual
- Interventions
- Fragmin P Forte (dalteparin sodium); Multivitamin supplement
- Study type
- INTERVENTIONAL
- Phase
- Phase 3
- Registry status
- Completed
- Start
- 2006-11
- Completion
- 2013-04
- Enrolment
- 449
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionAbortion, HabitualInterventionFragmin P Forte (dalteparin sodium); Multivitamin supplementPhasePhase 3Registry statusCompletedTrial of Vitamins Among Children of HIV-infected Women
NCT00197730 · start 2004-06
Registered record
- Registry ID
- NCT00197730
- Conditions
- HIV Infections; Pregnancy Complications
- Interventions
- Multivitamins - vitamins B complex, C and E; Placebo
- Study type
- INTERVENTIONAL
- Phase
- Phase 3
- Registry status
- Completed
- Start
- 2004-06
- Completion
- 2008-05
- Enrolment
- 2,387
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionHIV Infections; Pregnancy ComplicationsInterventionMultivitamins - vitamins B complex, C and E; PlaceboPhasePhase 3Registry statusCompletedLactate Metabolism Study in HIV Infected Persons
NCT00202228 · start 2002-07
Registered record
- Registry ID
- NCT00202228
- Conditions
- HIV Infections; AIDS; Lactic Acidosis; Lipodystrophy
- Interventions
- cofactor supplementation (thiamine, riboflavin, L-carnitine)
- Study type
- INTERVENTIONAL
- Phase
- Phase 4
- Registry status
- Completed
- Start
- 2002-07
- Completion
- 2011-09
- Enrolment
- 30
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionHIV Infections; AIDS; Lactic Acidosis; LipodystrophyInterventioncofactor supplementation (thiamine, riboflavin, L-carnitine)PhasePhase 4Registry statusCompletedVitamin B Therapy for Hyperlactatemia
NCT00031057
Registered record
- Registry ID
- NCT00031057
- Conditions
- HIV Infections
- Interventions
- Thiamine hydrochloride; Riboflavin
- Study type
- INTERVENTIONAL
- Phase
- Not applicable
- Registry status
- Completed
- Start
- Not recorded
- Completion
- Not recorded
- Enrolment
- 225
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionHIV InfectionsInterventionThiamine hydrochloride; RiboflavinPhaseNot applicableRegistry statusCompleted